Previous 10 | Next 10 |
YAVNE, Israel, Feb. 18, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the ...
YAVNE, Israel, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its agreement with GENFA MEDICA SA, grantin...
MediWound (NASDAQ: MDWD ) and its commercial partner Vericel (NASDAQ: VCEL ) announces that the U.S. Biomedical Advanced Research and Development Authority (BARDA), has begun procuring NexoBrid for emergency stockpile as part of the U.S. Department of Health and Human Servic...
YAVNE, Israel and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) within the Assistant Secretary ...
MediWound (NASDAQ: MDWD ) is up 10% premarket on signing a distribution agreement granting Balance Medical Pty Ltd. the exclusive rights to market and distribute NexoBrid in Australia, New Zealand and Singapore for the treatment of severe burns. More news on: MediWo...
YAVNE, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the signing of a distribution agreement granting Balance Med...
MediWound ( MDWD -1.2% ) initiates a Phase 2 clinical trial evaluating EscharEx, a topical biologic designed to enzymatically debride (remove dead tissue) chronic wounds, for the treatment of venous leg ulcers. More news on: MediWound Ltd., Healthcare stocks news, Read more ...
YAVNE, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (the “Company”) (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the initiation of patient trea...
MediWound Ltd. (MDWD) Q3 2019 Earnings Conference Call November 14, 2019, 08:30 AM ET Company Participants Jeremy Feffer - IR Sharon Malka - CEO Boaz Gur-Lavie - CFO Conference Call Participants Anthony Petrone - Jefferies & Co. Bryan Bergin - Cowen Presentation ...
MediWound (NASDAQ: MDWD ): Q3 GAAP EPS of -$0.11 beats by $0.04 . More news on: MediWound Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...
YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a definitive share purchase agreement with several new and existing investors, including Mölnlycke...